Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23523849 | 1.00 | MAOB (0.67) | MAOBALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL23523827 | 0.82 | SMN1; SMN2 (0.67) | ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL30355578 | 0.82 | SMN1; SMN2 (0.67) | ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL30355443 | 0.78 | SMN1; SMN2 (0.65) | ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL23524201 | 0.78 | SMN1; SMN2 (0.65) | ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL2414042 | 0.78 | S1PR1 (1.00) | MAOBS1PR1TRPA1 | |
| SCHEMBL2421742 | 0.77 | S1PR1 (1.00) | MAOBSMN1; SMN2NPC1S1PR1 | |
| SCHEMBL2772770 | 0.77 | S1PR1 (0.93) | ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL20968182 | 0.76 | MAOB (0.60) | MAOBALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2771674 | 0.76 | S1PR1 (1.00) | ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | MAOB 3653/4885ALDH1A1 2583/4885RAB9A 3056/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | MAOB 2715/4885ALDH1A1 1143/4885RAB9A 2056/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | MAOB 3653/4885ALDH1A1 2583/4885RAB9A 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.